US · Healthcare · Drug Manufacturers - General
EPS came in at -6.75 against a street estimate of -7.07 — a beat of 4.5%.
Analysts rate Gilead Sciences Inc a buy (19 buy, 11 hold, 0 sell out of 30) with an average price target of $157.41.
CONFIDENT Gilead delivered 10% base business growth on HIV strength (especially PrEP at $4B run rate) and Trodelvy oncology gains. Raised FY26 guidance; expects 2 launches H2. Pipeline remains robust across HIV, liver disease, and oncology. Q2 2026 Europe contributing to Livdelzi uptake. Global data shared for islatravir/lenacapavir at IAS meeting in Brazil. Analysts pressed on Yeztugo–Descovy competitive dynamics, persistency drivers, and ISL/LEN cannibalization risks. Management emphasized market expansion, complementary positioning, and switch-market focus; no major cannibalization expected. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.60% |
| Vanguard Capital Management, LLC | 6.50% |
| FMR Inc | 5.80% |
| State Street Corp | 4.83% |
| Amvescap Plc. | 3.35% |
| Capital World Investors | 3.31% |
| Vanguard Portfolio Management, LLC | 2.83% |
| JPMorgan Chase & Co | 2.74% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 GILEAD SCIENCES, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues (6M 2026): $14,763 million vs. $13,749 million (6M 2025), +7.4% incre | 2026-08-06 |
| Results announced · Q3 2026 GILEAD SCIENCES Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenues: $7.8 billion, up 10% year-over-year • Q2 2026 Product Sales: $7. | 2026-08-04 |
| Material agreement · Q2 2026 GILEAD SCIENCES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company issued $3,000,000,000 in new senior notes across four tranches on May 20, 2026 • | 2026-05-20 |
| Quarterly report · Q1 2026 GILEAD SCIENCES, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues Q1 2026: $6,960 million (Q1 2025: $6,667 million) – up 4.4% • Product | 2026-05-07 |
| Results announced · Q2 2026 GILEAD SCIENCES Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total Q1 2026 revenues: $7.0 billion, up 4% year-over-year • Product sales: $6.9 billion | 2026-05-07 |
| Shareholder vote results · Q2 2026 GILEAD SCIENCES, INC. – 2026 ANNUAL MEETING SUMMARY HEADLINE NUMBERS • Annual meeting held April 30, 2026 • Total shares entitled to vote: 1,241,222 | 2026-05-04 |
| Proxy statement · Q2 2026 GILEAD SCIENCES, INC. PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect nine director nominees to the Board (Annual Meetin | 2026-03-20 |
| Annual report FY2025 GILEAD SCIENCES, INC. - 2025 FORM 10-K SUMMARY --- HEADLINE NUMBERS • Market value of public float (as of last day of Q2 2025): $103.2 billion • Sh | 2026-02-24 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.82 / share ex-date Sep 15, 2026 · pay Sep 29, 2026 | 2026-09-15 |
| Dividend | $0.82 / share ex-date Jun 15, 2026 · pay Jun 29, 2026 | 2026-06-15 |
| Dividend | $0.82 / share ex-date Mar 13, 2026 · pay Mar 30, 2026 | 2026-03-13 |
| Dividend | $0.79 / share ex-date Dec 15, 2025 · pay Dec 30, 2025 | 2025-12-15 |
| Dividend | $0.79 / share ex-date Sep 15, 2025 · pay Sep 29, 2025 | 2025-09-15 |
| Announcement | Date |
|---|---|
| Completed acquisition of Arcellx, Inc. for $115 per share plus CVR Gilead Sciences completed its acquisition of Arcellx on April 28, 2026, for approximately $7.1 billion. Shareholders received $115 per share in cash plus one contingent value right (CVR) wor | 2026-04-28 |
| Gilead to acquire Arcellx for $115 per share plus contingent payments Gilead Sciences agreed to acquire Arcellx, Inc. for $115 per share in cash plus one contingent value right (CVR) worth up to $5 per share upon achieving a specified milestone. The total deal | 2026-02-23 |
| Settlement agreements resolve patent litigations, generic entry delayed to 2036 Gilead Sciences announced settlement agreements with three generic drug manufacturers (Lupin, Cipla, and Laurus Labs) to resolve patent litigation over generic versions of Biktarvy, a major | 2025-10-06 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gilead Sciences Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.